Literature DB >> 29138285

Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.

Charlotta Hedner1, David Borg1, Björn Nodin1, Emelie Karnevi1, Karin Jirström1, Jakob Eberhard1.   

Abstract

AIMS: Neoadjuvant treatment has now become the standard of care for oesophageal and gastric cancer. The aim of this study was to investigate the influence of neoadjuvant therapy on the expression of human epidermal growth factor receptor 1 (HER1/EGFR), HER2 and HER3, in oesophageal and gastric adenocarcinoma.
METHODS: Immunohistochemical expression of EGFR, HER2 and HER3 was examined and compared in pretreatment biopsies, post-treatment surgical resection specimens and metastases in a retrospective cohort of 166 patients with adenocarcinoma of the oesophagus or stomach. The relationship between expression of the investigative markers and histopathological response to neoadjuvant treatment, overall survival (OS) and recurrence free survival (RFS) was analysed.
RESULTS: Conversion of protein expression between pretreatment biopsy and post-treatment surgical resection was seen in 4.6% of the cases for EGFR, 5.9% for HER2% and 19.4% for HER3. Histopathological response to neoadjuvant treatment was significantly and stepwise associated with OS and RFS . High HER3 protein expression in post-treatment surgical resection specimens was significantly associated with a prolonged OS in univariable analysis (HR=0.39; 95% CI 0.17 to 0.93), but did not remain significant in multivariable analysis. Expression of EGFR and HER2 in post-treatment surgical resection specimens was not prognostic. No correlation between pretreatment HER-protein expression and histopathological response was seen.
CONCLUSIONS: The results from this study underscore the need for further studies on the influence of neoadjuvant treatment on biomarker expression, as this may influence treatment strategy as well as prognosis. Histopathological response is validated as a useful prognostic factor. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  histopathology; immunohistochemistry; in situ hybridisation; oesophagus; stomach

Mesh:

Substances:

Year:  2017        PMID: 29138285     DOI: 10.1136/jclinpath-2017-204774

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.

Authors:  Patrícia M R Pereira; Komal Mandleywala; Ashwin Ragupathi; Lukas M Carter; Jeroen A C M Goos; Yelena Y Janjigian; Jason S Lewis
Journal:  J Nucl Med       Date:  2019-06-06       Impact factor: 10.057

2.  T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.

Authors:  Maria Christina Svensson; Albin Lindén; Jakob Nygaard; David Borg; Charlotta Hedner; Björn Nodin; Karin Leandersson; Karin Jirström
Journal:  Oncoimmunology       Date:  2021-05-20       Impact factor: 8.110

3.  Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.

Authors:  Emma Sandén; Somayeh Khazaei; Helga Tryggvadottir; Signe Borgquist; Karolin Isaksson; Karin Jirström; Helena Jernström
Journal:  Virchows Arch       Date:  2020-02-20       Impact factor: 4.064

4.  Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.

Authors:  David Borg; Anna H Larsson; Charlotta Hedner; Björn Nodin; Anders Johnsson; Karin Jirström
Journal:  J Transl Med       Date:  2018-10-24       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.